MedTrace Logo

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

NCT07203287 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is

"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Conditions

  • Post Operative Pulmonary Complications
  • Neuromuscular Blockade
  • General Anesthesia

Interventions

DRUG

Rocuronium

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUG

Cisatracurium

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

DRUG

Sugammadex

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUG

Neostigmine

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • Michael Kinsky, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2026-12-31
Completion
2027-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07203287 on ClinicalTrials.gov